ArticleFrontiers in immunology2019
Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.Inflammopharmacology · 2025Pooled it
- A Systematic Review of Interleukin-17 in Oral Lichen Planus: From Etiopathogenesis to Treatment.Clinical medicine & research · 2023Pooled it
- Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.Archives of dermatological research · 2022Pooled it
- Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.The British journal of dermatology · 2022Trial
- Bacterial Involvement in Oral Squamous Cell Carcinoma and Potentially Malignant Oral Disorders.Oral diseases · 2026Observational
- The Autoimmune March: Bullous Lichen Planus and New-Onset Lupus Erythematosus Occurring After COVID-19 mRNA Vaccination in a Filipino Female With Rheumatoid Arthritis.Clinical case reports · 2025Article
- Lichen planus-the role of age and gender in clinical appearance and treatment : A narrative review.Wiener medizinische Wochenschrift (1946) · 2025Review
- Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence.Antibodies (Basel, Switzerland) · 2025Review
- Successful Treatment of Annular Atrophic Lichen Planus With Adalimumab.Clinical case reports · 2025Article
- Mechanisms Underlying Lichen Planus in Association with Biologic Therapy.Journal of inflammation research · 2025Review
- CXCL9, CXCL10, and CCL19 synergistically recruit T lymphocytes to skin in lichen planus.JCI insight · 2024Article
- Immunohistochemical examination of immunoreactivity of transient receptor potential melastatin 2, glutathione peroxidase 4 and spexin in lichen planus.Archives of dermatological research · 2024Review
- Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions.Immune network · 2024Review
- Distinct Variations in Gene Expression and Cell Composition across Lichen Planus Subtypes.International journal of molecular sciences · 2024Article
- Lichen Planus: What is New in Diagnosis and Treatment?American journal of clinical dermatology · 2024Review
- Guselkumab - In Psoriasis and Beyond.Dermatology practical & conceptual · 2024Review
- Integrative Approaches for the Diagnosis and Management of Erosive Oral Lichen Planus.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Treatment of oral lichen planus using deucravacitinib.JAAD case reports · 2024Article
- Dysbiosis and interactions of the mycobiome and bacteriome in mucosal lesions of erosive and non-erosive oral lichen planus patients.Journal of oral microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Lichen planus (LP) is a common, chronic relapsing inflammatory disorder of the skin and mucous membranes which often poses a major therapeutic challenge due to its refractory course. Novel pathogenesis-based therapies are urgently needed. As several studies have shown that IL-17 may contribute to LP pathogenesis, we investigated whether therapeutic targeting of IL-17
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.